Payers & risk-bearing entities
The most expensive covered lives — and no one is managing them.
Post-treatment cancer survivors are the highest-cost, most-fragmented slice of your book. Life Spark is the branded, protocol-driven, franchisable survivorship home that reduces ED, duplicative imaging, and readmissions — with HEDIS-aligned reporting from day one.
The cost math
- 3.2×
- matched-cohort medical spend in the first 24 months post-treatment (JAMA Oncology)
- 38%
- of survivor ED visits are for issues addressable in primary/survivorship care (AHRQ)
- $712
- average out-of-pocket per survivor per year on coordination they can't find
- 22.5M
- projected U.S. survivors by 2032 — the covered-lives math changes every year
Partnership models
Four ways to contract. Every one is measured.
Commercial value-based contracting
Shared-savings agreements on a survivorship-attributed cohort. Metrics: ED utilization, duplicative imaging, 30-day readmit rate, care-plan documentation.
Medicare Advantage network partner
In-network survivorship coverage across Life Spark territories. HEDIS-aligned reporting on colorectal, breast, and cervical screening for the survivor sub-population; care-plan documentation for Stars.
ACO / risk-bearing entity
Sub-capitated survivorship carve-out for ACOs holding downside risk. We take on the post-treatment attributed lives and report against agreed metrics quarterly.
Self-insured employer
Cancer is now the #1–#2 spend line for large self-insured employers. We contract directly with benefits leaders and TPAs as a survivorship point solution.
Quality metrics we report on
HEDIS-aligned. Guideline-anchored. Contractable.
| Metric | Contract-ready goal | Standard |
|---|---|---|
| Care-plan documentation rate | ≥90% within 90 days of enrollment | IOM 'Lost in Transition', HEDIS-aligned |
| Cancer screening completion (breast, cervical, colorectal) | ≥85% of due survivors within calendar year | USPSTF, NCCN, HEDIS |
| Cardio-oncology surveillance | ≥95% of anthracycline/chest-XRT survivors on schedule | ASCO Cardio-Oncology Guideline |
| ED utilization (survivorship cohort) | ≥15% reduction vs. matched baseline by year 2 | AHRQ HCUP baselines |
| 30-day readmission (post-oncology admit) | ≥20% reduction vs. matched baseline by year 2 | CMS QualityNet baselines |
| Duplicative imaging (CT/MRI within 30 days) | ≥25% reduction vs. matched baseline | Choosing Wisely / ASCO |
Illustrative contractable targets. Final baselines are set jointly during a 90-day cohort attribution and matched-comparator build.
Ready to run the numbers on your book?
Our actuarial team will build a survivorship cohort attribution on your de-identified claims and return a spend, utilization, and savings model within 30 days.